Courtney Fitzhugh

Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait.

Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy.

Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease.

Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma.

Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?

Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.

Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease.

Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

Angioedema in patients treated with sirolimus and ACE inhibitor post hematopoietic SCT.

Gout and sickle cell disease: not all pain is sickle cell pain.

Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait.

Severe cardiac iron toxicity in two adults with sickle cell disease.

Measurements of red cell deformability and hydration reflect HbF and HbA2 in blood from patients with sickle cell anemia.

Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.

Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease.

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.

Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies.

Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study.

Alternative Donor/Unrelated Donor Transplants for the β-Thalassemia and Sickle Cell Disease.

Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia.